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Stephan von Gunten 1 and Hans-Uwe Simon 1
Over millions of years, the skeletal and the immune sys-
tems have coevolved in the development from bony fish to
terrestrial animals to form a symbiotic and highly interactive
relationship. It has been suggested that environmental pres-
sures, such as higher levels of UV light and oxygen, or lower
levels of calcium in the terrestrial environment, promoted the
establishment of the protective endosteal niche for haema-
topoietic stem cells (HSCs) in the bone marrow1. Besides
other aspects, the tight connection between the immune and
the skeletal systems is reflected by the following facts: (1)
origination of osteoclasts from hematopoietic progenitor
cells, (2) colocalization of osteoblast and osteoclast pro-
genitor cells with immune cell progenitor and memory cells
in the bone marrow, (3) immunomodulatory effects of the
major pro-osteoclastogenic cytokine receptor activator of
NF-κB ligand (RANKL) and its expression by both osteoblast
lineage cells and lymphocytes, (4) reciprocal effects of
immune and bone remodelling cells in cell differentiation
and bone remodelling, and (5) reduction of bone mass in
inflammatory disorders, eventually as a consequence of
excessive bone resorption2. In the last two decades, sig-
nificant new insights into the complex interaction between
the immune and skeletal systems brought light to the
research field, which was referred to as ‘osteoimmunology’ by
Arron and Choi in 20003.
Glucocorticoids (GCs) exhibit a plethora of genomic and
non-genomic effects in different tissues4, and significantly
influence both bone remodelling and immune cells. High
GC exposure, as it occurs in steroid therapy, has catabolic
effects on bones and can result in osteoporosis. In fact,
GC-induced osteoporosis (GIOP) is the most frequent
cause of secondary osteoporosis5. The pharmacological
effects of exogenous GCs in osteoporosis induction remain
only partly understood, yet may include negative effects on
differentiation, proliferation, survival, and function of
osteoblasts and osteocytes, eventually involving Wnt sig-
nalling pathways, the transcription factors AP-1 and
Notch, as well as specific miRNAs5. Besides direct effects
on osteoclasts and their precursors, GCs may stimulate
osteoclastogenesis by induction of RANKL and reduce
expression of osteoprotegerin (OPG), a decoy receptor of
RANKL, in osteoblastic cells and osteocytes6–8.
In this issue of Cell Death and Disease, Song et al.9 report
a central role of T cells for GIOP (Fig. 1). Using models with
T-cell-deficient SCID or nude mice, they demonstrated that
T cells are indispensable for the establishment of GIOP.
SCID mice develop osteoporosis upon adoptive transfer of
T cells, which was paralleled by an increase of RANKL in
serum. T cells homing in the bone marrow were found to
express RANKL and were able to stimulate ex vivo the
differentiation of osteoclasts in co-culture experiments with
myeloid RAW264.7 cells. Given that in other types of
osteoporosis T-cell-derived cytokines have been shown to
enhance RANKL expression in osteoblasts and other
cells10,11, it is possible that such indirect effects also con-
tribute mechanistically to the development of GIOP.
Peripheral lymphopenia can result from impaired lym-
phopoiesis in the endosteal niche due to diminished IL-7
production by osteoblasts, as observed under septic condi-
tions12. In contrast, while dexamethasone treatment resulted
in the reduction of circulating T-cell numbers and an increase
of apoptotic T cells in the spleen, Song et al.9 observed an
accumulation of viable T cells in the bone marrow, suggesting
a protective influence of the endosteal niche. The increased
T-cell homing to the bone marrow was found to be depen-
dent on chemokine ligand receptor interactions with sig-
nificant involvement of the CXCL10-CXCR3 axis. CXCL10
and CXCR3 receptor signalling have previously been linked
to bone loss related to increased osteoclast differentiation and
activity in various models of disease2, including conditions
with an established pathogenic role of T cells.
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The study by Song et al. highlights the importance of
T cells in the pathogenesis of GIOP and may support the
consideration of osteoimmunological approaches in the
prevention of GIOP. However, while the existing literature
documents distinct contributions of T-cell subsets, cyto-
kines, and chemokines in the development of osteo-
porosis1,10,11, their relevance to GIOP remain to be explored.
Furthermore, it will be important to consider that significant
differences in immune responses exist not only between
species13,14, but also among human individuals15,16. Future
pharmacotherapeutic strategies are expected to be inspired
by a better understanding of molecular networks17, and the
mutual interactions between the bone and immune systems
in GIOP, eventually resulting in more personalized approa-
ches to steroid therapy.
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Fig. 1 Proposed involvement of T cells in glucocorticoid-induced osteoporosis. While peripheral T cells may undergo apoptosis upon exposure
to dexamethasone, some T cells accumulate in the bone marrow in a CXCL10-CXCR3 axis-dependent manner. Latter T cells are protected from cell
death and promote RANKL-induced osteoclastogenesis. Illustration by Aldona von Gunten. GIOP glucocorticoid-induced osteoporosis, RANK receptor
activator of NF-κB, RANKL RANK ligand.
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